Paratek’s antibiotic succeeds in Phase IIb lung disease trial
Boston-based Paratek Pharmaceuticals has released positive topline data from a Phase IIb trial evaluating its oral antibiotic Nuzyra (omadacycline) in…
Infectious Disease
-
-
Hurricane Helene delays Spectral Medical’s confirmatory trial enrolment
Spectral Medical will have to wait to submit an application to the US Food and Drug Administration (FDA) for its…
-
Spero’s stock slides after antibiotic flops in Phase II trial
Spero Therapeutics has suspended the development of its antibiotic SPR720, after the therapy failed to meet the primary endpoint in a Phase…
-
Bavarian eyes mpox vaccine label expansion to include toddlers, kickstarts Phase II trial
Bavarian Nordic is looking to expand the approval label of its MVA-BN mpox/smallpox vaccine to include children between two and…
-
MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win
MSD (Merck & Co) is planning to get its RSV vaccine, clesrovimab, approved and launched before the next RSV season…
-
MSD’s CAPVAXIVE vaccine shows promise in pneumococcal disease trial
MSD’s CAPVAXIVE vaccine has demonstrated promising results from the STRIDE-8 Phase III trial, which showed positive immune responses in adults…
-
Innovent’s trial of picankibart for ulcerative colitis meets primary endpoint
Innovent Biologics has reported that its Phase II clinical trial of picankibart (IBI112) in Chinese patients with moderately to severely…
-
ImCheck scores $22.4m in French funding to develop cancer antibody
ImCheck Therapeutics has received €20.18m ($22.35m) in non-dilutive funding from the French government to advance its pipeline. The funds were…
-
Spectral Medical’s revenue up 54% as company eyes Tigris trial completion
Spectral Medical has reported a 54% rise in revenue for the second quarter as the Canadian company looks ahead to…
-
AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial
AN2 Therapeutics has implemented cost-saving measures after “disappointing” topline results from Phase II part of the Phase II/III trial evaluating…
